Browse Guides  internal medicine  cardiology

Congestive heart failure

Prevalence
Causes
Clinical features
Differential diagnosis
Investigations
Therapy
Prevention
Prognosis
Prevention

There is no benefit from phosphodiesterase inhibitors a

Why?

  • Phosphodiesterase inhibitors increase the risk of dying. a

Phosphodiesterase inhibitors increase the risk of dying

Patient Treatment Comparison Outcome CER OR
(95% CI)		 NNH
(95% CI)
overt chronic heart failure a phosphodiesterase inhibitors (except vesnarinone) placebo death
at 3 months 		17% 1.42
(1.13 to 1.80) 		18 (10 to 15)
 

 

Expiry date: June 2003
Levels of Evidence used in grading these guides

Author   CM   Ball
Reviewer   B   Lee
CAT Writers   CM   Ball , CJ   Wotton , A   Yates